It also provides a strong rationale for the understanding of the role of the SRC‐family in BRAFi treatment (Girotti et al, 2015; Close et al, 2020; Krayem et al, 2020) and allows to delineate the pathway that mediates the activation of SRC and elevated integrin/FAK observed in melanoma (Hirata et al, 2015). This evidence concerns the gene PTK2 and melanoma.